Overview

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Henan Cancer Hospital
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib